apy were excluded. Etiology of systolic CHF was ischemic cardiomyopathy (n=213), dilated cardiomyopathy (n=72), or hypertensive heart disease (n=68). The New York Heart Association functional class was evaluated on the day of cardiac catheterization. Informed consent was obtained from all patients for participation in the study, following protocol approved by the Committee on Human Investigation at our institution. This was the same study population as in our previously reported study (n=366), 16 although 13 patients who could not be followed were excluded.
Study Protocol
All patients were given an oral dose of diazepam (5 mg) and instructed to rest in bed in a supine position for at least 20 min. Left-sided cardiac catheterization was performed and blood pressure was measured. Heart rate was monitored by electrocardiography. Blood samples for measurement of plasma BNP and NT-proBNP were collected simultaneously from the aortic root (AO) and coronary sinus (CS). A 6-Fr catheter for blood sampling was positioned in the CS, and the position of the catheter was confirmed as instructed elsewhere. 17 Blood samples from the AO were also collected for measuring creatinine and norepinephrine. Left ventriculography was performed using contrast medium or radioisotope before or at least 1 week after hemodynamic measurements and blood sampling. Renal function was represented by the estimated glomerular filtration rate (eGFR) according to the Cockcroft -Gault equation.
Measurement of BNP and NT-ProBNP
Samples for the assay of plasma BNP and NT-proBNP concentrations were transferred to chilled disposable tubes containing aprotinin (500 kallikrein inactivator units/ml). The blood samples were placed immediately on ice and centrifuged at 4°C, and the plasma was frozen in aliquots and stored at -30°C until required for assay. Plasma BNP concentrations were measured with a specific immunoradiometric assay for human BNP using a commercial kit (Shionogi), as reported elsewhere. 1 Plasma levels of NTproBNP were measured using the Elecsys proBNP sandwich immunoassay (Roche Diagnostics), as reported elsewhere. 10 
Statistical Analysis
All results are expressed as the mean ± SD. A chi-square test was used to determine differences between groups. Univariate analyses were performed using Student's t-test. Differences in mean levels of BNP, NT-proBNP and the molar ratio of (CS-AO) NT-proBNP to (CS-AO) BNP between the 2 groups were tested by Wilcoxon rank-sum test for paired value and by Mann -Whitney's U-test for unpaired value with 2-tailed p-values of <0.05, and log BNP and log NT-proBNP was used for correlations and regression models. On multivariable Cox proportional hazard analyses, the main models were adjusted for age, gender, and variables considered to reflect the severity of CHF at baseline and then those were associated with mortality on univariate analyses at the p<0.10 level. Multivariable Cox proportional hazard analyses were performed as stepwise regressions with backward elimination. Kaplan -Meier analysis was performed on the cumulative rates of survival stratified into 2 groups based on the median value of the transcardiac gradient of NT-proBNP to BNP molar ratio, and the differences between survival curves were analyzed by log-rank test.
Non-survivors Survivors

Log molar ratio of (CS-AO) NT-proBNP/(CS-AO)BNP Log molar ratio of (CS-AO) NT-proBNP/(CS-AO)BNP Log molar ratio of (CS-AO) NT-proBNP/(CS-AO)BNP Log molar ratio of (CS-AO) NT-proBNP/(CS-AO
The sensitivity and specificity of BNP and NT-proBNP for predicting mortality were determined, and receiver operating characteristics (ROC) curves were constructed. A value of p<0.05 was considered significant. Table 1 summarizes patient characteristics according to survival. During a median follow-up of 2.8 years, 35 patients died. The molar ratio of (CS-AO) NT-proBNP to (CS-AO) BNP was significantly higher in non-survivors than survivors (median value =0.702 vs 0.437, respectively; p=0.0009) (Fig 1) .
Results
Patient Characteristics
Comparison of NT-ProBNP Secretion to BNP Secretion in Patients With CHF
Patients were divided into 2 groups based on the median molar ratio of (CS-AO) NT-proBNP to (CS-AO) BNP (group 1: molar ratio of (CS-AO) NT-proBNP to (CS-AO) BNP <0.444; group 2: molar ratio of (CS-AO) NT-proBNP to (CS-AO) BNP >0.444) ( Table 2 ). There was no difference of left ventricular ejection fraction (LVEF), left ventricular end-diastolic pressure (LVEDP) and eGFR between the 2 groups ( Table 2 ). Plasma levels of norepinephrine and NTproBNP were significantly higher in group 2 than in group 1 ( Table 2 ). The use of angiotensin-converting enzyme inhibitor, angiotensin receptor blockers, and -blockers was less in group 2 than in group 1. The molar ratio of (CS-AO) NT-proBNP to (CS-AO) BNP correlated with LVEDP, LVEF, heart rate and plasma norepinephrine (Fig 2) . Mortality rate was significantly higher in group 2 than in group 1 (Fig 3) . 
Univariate and Multivariable Predictors of Mortality: Comparison of BNP, NT-ProBNP and Hemodynamic Parameters
Twelve clinical, neurohumoral and hemodynamic variables were analyzed using univariate and stepwise multivariable Cox proportional hazard regression analyses (Table 3) . On stepwise multivariable analyses, only a high level of plasma log NT-proBNP (p<0.0001) was a significantly independent predictor, even after considering the transcardiac increases in BNP and NT-proBNP (Table 3) . ROC curves of BNP and NT-proBNP demonstrating mortality risks are shown in Fig 4. There was no difference in the area under the curve for predicting mortality between BNP and NTproBNP, although there was a slightly higher value for NTproBNP compared with BNP. The cut-off level for BNP was determined as 93 pg/ml, giving a sensitivity of 91% and specificity of 56%. The cut-off level of NT-proBNP was determined as 627 pg/ml, giving a sensitivity of 91% and specificity of 55%.
Discussion
Few studies have directly compared the prognostic value of BNP and NT-proBNP in patients with CHF. 13, 18, 19 In the present study we measured the transcardiac increase of BNP and NT-proBNP and hemodynamic parameters in patients with CHF, and then evaluated the prognostic value of BNP and NT-proBNP in a head-to-head comparison between 2 commercially available assays (BNP, Shionogi; NT-proBNP, Roche). In the present study, we showed, for the first time, that the transcardiac gradient of NT-proBNP to BNP molar ratio correlated with hemodynamic abnormalities (Fig 2) and it was significantly higher in non-survivors than in survivors (Fig 1) , suggesting that NT-proBNP is superior to BNP in terms of their transcardiac increase for evaluating the severity and prognosis of patients with CHF.
Based on our previous observations, there was no significant difference in the levels of plasma BNP and NT-proBNP between the AO and antecubital vein in patients with CHF (data not shown). After adjustment for clinical variables associated with CHF, including hemodynamics and eGFR, only the plasma NT-proBNP level was an independent prognostic predictor by Cox proportional analysis, even after considering the transcardiac increases in BNP and NT-proBNP. There was no difference in the area under the ROC curve for predicting mortality between BNP and NT-proBNP, although there was a slightly higher value for NT-proBNP compared with BNP (Fig 4) . Therefore, a head-to-head comparison of their prognostic value showed that the 2 biomarkers were substantially equivalent 18, 19 and that NTproBNP performed slightly better than BNP, which was consistent with the recent study of the Val-HeFT study population by Masson et al, 13 using the same commercial kits. The present findings may support their observations by direct sampling from the AO and CS.
BNP is synthesized as pro-BNP in cardiac myocytes, and then pro-BNP is transformed to hormonally active BNP and inactive NT-proBNP. BNP and NT-proBNP are thought to be secreted from the heart in equimolar amounts. 7, 8 In addition, BNP and NT-proBNP and pro-BNP are secreted in the bloodstream. 9 Therefore, at least 3 molecular forms (ie, pro-BNP, BNP and NT-proBNP) are found in the plasma. 9, 11, 12 Plasma BNP and NT-proBNP levels in the present study were comparable with baseline values of BNP and NTproBNP shown in a recent study by the Val-HeFT group, 13 using the same commercial kits. Unexpectedly, the molar ratio of the transcardiac increase in NT-proBNP to the transcardiac increase in BNP showed wide variation with a mean value of <1. Interestingly, the transcardiac increase in NT-proBNP to BNP molar ratio was significantly higher in non-survivors than in survivors (Fig 1) , suggesting that the molecular forms of BNP may change with the severity of CHF. The Triage Biosite BNP assay gives a value that is approximately 50% higher than that of the Shionogi assay. 20 Therefore, if the Triage BNP assay kit is used, the transcardiac increase of NT-proBNP to BNP molar ratio would be lower than that found in the present study. It is important to note that immunoreactive moiety detected by any given immunoassay depends on the combined influence of circulating forms of BNP, the degree and/or C-terminals, and the epitopes to which polyclonal or monoclonal antibodies have been raised. 21 In the present study, a high level of plasma NT-proBNP was a significantly independent predictor, even after considering the transcardiac increases in BNP and NT-proBNP. The reason why plasma NT-proBNP is more useful for predicting mortality than transcardiac increase in NT-proBNP cannot be explained easily. In previous studies, including ours, parameters such as LVEDP, LVEF, left ventricular (LV) mass index, anemia (hemoglobin) and renal function (eGFR) were confirmed as prognostic markers, respectively, influencing the plasma levels of BNP and NTproBNP. 10, 16, 22, 23 Hence, a single measurement of BNP and NT-proBNP in plasma may be a stronger prognostic indicator than hemodynamics and the transcardiac increases in BNP and NT-proBNP in patients with CHF.
There are several limitations in the present study. The molecular forms of the blood samples for assays of BNP and NT-proBNP could not be evaluated, and further studies are needed to clarify this issue using radioimmunoassay combined with gel chromatography or high performance liquid chromatography. Being unable to determine the total amount of cardiac secretion of BNP and NT-proBNP because coronary blood flow was not measured is also a limita- tion of the present study. The small number of deaths is also a limitation; however, BNP and NT-proBNP were measured in the AO and CS, and hemodynamics were evaluated in the present study. Furthermore, information on the relationship between the transcardiac gradient of the NT-proBNP to BNP ratio and the hemodynamic abnormality and mortality suggests that studies to identify the various molecular forms of BNP are needed to confirm the usefulness of the assay of their peptides in patients with CHF.
In conclusion, the transcardiac gradient of NT-proBNP to BNP molar ratio increases with the severity of LV dysfunction and is significantly higher in non-survivors than in survivors, suggesting that the plasma NT-proBNP level may be more useful than that of BNP for evaluating the prognosis of patients with CHF.
